Atazanavir: A novel HIV-1 protease inhibitor

Expert Opinion on Investigational Drugs

Volumn 11, Issue 9, 2002, Pages 1295-1301

  Piliero, Peter J ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

Author keywords

Atazanavir; HIV 1; Protease inhibitor

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDINAVIR; KETOCONAZOLE; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RIFABUTIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CAPSULE; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TOLERABILITY; DYSLIPIDEMIA; GASTROINTESTINAL SYMPTOM; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; MORBIDITY; MORTALITY; PERIPHERAL NEUROPATHY;

ANIMALS; CLINICAL TRIALS; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; OLIGOPEPTIDES; PYRIDINES;

EID: 0036736496     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.11.9.1295     Document Type: Article

References (34)

1. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial
2. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter
3. The retroviral enzymes
4. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
5. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
6. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults
7. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection
8. Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults
9. Addressing the challenges of adherence
10. Clinical evaluation and management of metabolic and morphologic abnormalities associated with human immunodeficiency virus
11. The prevalence of antiretroviral drug resistance in the US
12. Outcome of a second-line protease inhibitor-containing regimen in patients failing or intolerant of a first highly active antiretroviral therapy
13. Atazanavir: A once-daily protease inhibitor with a superior lipid profile-results of clinical trials at week 48
14. Atazanavir plus saquinavir once daily favorably affects total cholesterol (TC), fasting triglyceride (TG), and fasting LDL cholesterol (LDL) profiles in patients failing prior therapy
15. British HIV Association guidelines for the treatment of HIV-infected adults with antiretroviral agents
16. Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: Frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate
17. 'Hit later, hit hard' with AIDS drugs: Federal government to announce new AIDS treatment policy
18. BMS-232632
19. BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other antiretroviral agents
20. Human serum alpha 1 acid glycoprotein reduced uptake, intracellular concentration, and antiviral activity of A-80987, and inhibitor of the human immunodeficiency virus Type 1 protease
21. In vitro resistance profile of the Human Immunodeficiency Virus Type 1 protease inhibitor BMS-232632
22. BMS-232 sensitivity of a panel of HIV-1 clinical isolates resistant to one or more approved protease inhibitors
23. BMS-232632: Single-oral dose safety and pharmacokinetic study in healthy volunteers
24. BMS-232632: Single and multiple oral dose safety and pharmacokinetic study in healthy volunteers
25. Hollow-fiber unit evaluation of a new human immunodeficiency virus Type 1 protease inhibitor, BMS-232632, for determination of the linked pharmacodynamic variable
26. BMS-232632: A preliminary pharmacokinetic and pharmacodynamic evaluation of BMS-232632 in a protease inhibitor-naive HIV positive population
27. Steady-state pharmacokinetic interaction study between BMS-232632 and ketoconazole in healthy subjects
28. Pharmacokinetic effect of rifabutin on atazanavir with and without ritonavir in healthy subjects
29. Evaluation of the steady-state interaction between atazanavir and efavirenz
30. Pilot study of the interaction between BMS-232632 and ritonavir
31. Steady state pharmacokinetic interaction study of atazanavir with efavirenz and ritonavir in healthy subjects
32. The Genetic Basis of the Reduced Expression of Bilirubin UDP-Glucuronosyltransferase 1 in Gilbert's Syndrome
33. Relationship between uridine diphosphate-glucuronosyl transferase (UDP-GT) 1A1 genotype and total bilirubin elevations in healthy subjects receiving BMS-232632 and saquinavir (SQV)
34. Interaction Between Ritonavir and Statins